Devil's Claw for Health & Longevity - Quick Reference Sheet
evipedia.aidev
← Back

Devil's Claw for Health & Longevity

Created on 08/02/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A bitter African root with real but modest evidence for easing joint and low-back pain, working about as well as common pain drugs with fewer side effects. Stomach upset is the usual complaint. The studies are small and mostly funded by sellers, and nothing shows it slows aging or inflammation. (Full Review)

Protocol

Dose
50–60 mg harpagoside daily
Standardized aqueous extract or root powder
Schedule
Three divided doses
With breakfast, lunch, and evening meal
Fair trial
8–12 weeks
Minimum 8 weeks at full dose
Time to effect
Initial relief
2–4 weeks
Some pain reduction may appear
Adequate test
8 weeks
Judging earlier is premature
Maximal benefit
1–4 months
With continuous use

Benefits

Contraindications
  • Active or historical peptic ulcer or duodenal ulcer
  • Gallstones or bile duct obstruction
  • Pregnancy (any stage)
  • Breastfeeding
  • Children under 18
  • Hypersensitivity to Harpagophytum or Pedaliaceae
  • Surgery scheduled within 14 days
  • Severe hepatic impairment (Child-Pugh B or C)
  • Advanced kidney disease (eGFR below 30 mL/min/1.73 m²)
  • Direct oral anticoagulant use
    •
Key Interactions
  • Anticoagulants and antiplatelet agents (warfarin, direct oral anticoagulants, clopidogrel, aspirin)
  • NSAIDs (ibuprofen, naproxen, diclofenac, celecoxib)
  • Acid-suppressing medication (proton pump inhibitors, H2 blockers)
  • Glucose-lowering medication (insulin, glipizide, glyburide, metformin)
  • Antiarrhythmic, cardiac and blood-pressure medications (digoxin, amiodarone, beta-blockers, amlodipine, lisinopril)
  • Narrow therapeutic index drugs (lithium, phenytoin, ciclosporin, tacrolimus, methotrexate)
  • Over-the-counter medications (aspirin, ibuprofen, naproxen, antacids)
  • Antiplatelet or anticoagulant supplements (willow bark, fish oil, ginkgo, garlic, vitamin E, nattokinase)
  • Other interventions (fasting protocols, intra-articular corticosteroid or platelet-rich plasma injection)
    •

Risk & Side Effects

  • High: Gastrointestinal adverse effects
    •
  • Medium: Aggravation of peptic ulcer disease and upper gastrointestinal bleeding; provocation of gallbladder and bile duct symptoms
    •
  • Low: Minor non-gastrointestinal adverse events; allergic and skin reactions; uterine stimulation during pregnancy; blood pressure disturbance
    •
  • Speculative: Additive blood-sugar lowering; cardiac rate and conduction effects; interference with drug metabolism and transport
    •

Monitoring

Marker Target Why
Haemoglobin & Ferritin Hb 13.5–15.0 g/dL (women), 14.0–16.0 (men); ferritin 50–150 ng/mL Detects occult gastrointestinal blood loss
hs-CRP < 1.0 mg/L General inflammatory burden
ALT & AST ALT 10–26 U/L (men), 10–19 (women); AST 10–26 U/L Baseline liver function
Fasting Glucose & HbA1c Glucose 75–86 mg/dL; HbA1c 4.8–5.3% Reference for additive blood-sugar lowering
INR 0.9–1.1; within prescribed target (commonly 2.0–3.0) if on warfarin Detects the warfarin interaction before it becomes a bleeding event
eGFR & Creatinine eGFR ≥ 90 mL/min/1.73 m²; creatinine in lower half of range Baseline kidney function

Cadence: Baseline, then at 12 weeks, then every 6–12 months. INR at 2 and 4 weeks for warfarin users; intensified home glucose for the first 2–4 weeks on insulin or sulfonylureas.

Qualitative Assessment

  • Pain intensity on a 0–10 scale (at rest, on movement, worst in past 24 h)
  • Morning stiffness duration
  • Functional capacity (stair flights, walking distance, chair-rise time)
  • Analgesic tablet count
  • Digestive tolerance
  • Sleep continuity
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.